Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach

BMC Microbiology

Laurent Mallet¹  Lucy Gisonni-Lex¹  Mei Tang¹  Ali Azizi¹ 

[1] Microbiology & Virology Platform, Department of Analytical Research & Development North America, Sanofi Pasteur, 1755 Steeles Avenue West, Toronto, Ontario M2R 3 T4, Canada

关键词: Potency;    Vaccine;    RT-qPCR;    HSV type 2;    Infectious titre;   

Others  :  1142414
DOI  :  10.1186/1471-2180-13-284

 received in 2013-09-04, accepted in 2013-12-04,  发布年份 2013

【 摘 要 】

Background

One of the critical tasks in analytical testing is to monitor and assign the infectivity or potency of viral based vaccines from process development to production of final clinical lots. In this study, a high throughput RT-qPCR based approach was developed to evaluate the infectious titre in a replication-defective HSV-2 candidate vaccine, called HSV529. This assay is a combination of viral propagation and quantitative RT-PCR which measures the amount of RNA in infected cells after incubation with test samples.

Results

The relative infectious titre of HSV529 candidate vaccine was determined by a RT-qPCR method targeting HSV-2 gD2 gene. The data were analyzed using the parallel-line analysis as described in the European Pharmacopoeia 8^th edition. The stability of HSV529 test samples were also investigated in a concordance study between RT-qPCR infectivity assay and a classical plaque assays. A suitable correlation was determined between both assays using an identical sample set in both assays. The RT-qPCR infectivity assay was further characterized by evaluating the intermediate precision and accuracy. The coefficient of variation from the six independent assays was less than 10%. The accuracy of each of the assay was also evaluated in the range of 92.91% to 120.57%.

Conclusions

Our data demonstrate that the developed RT-qPCR infectivity assay is a rapid high throughput approach to quantify the infectious titer or potency of live attenuated or defective viral-based vaccines, an attribute which is associated with product quality.

【 授权许可】

   
2013 Azizi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Minagawa T, Sakuma T, Kuwajima S, Yamamoto TK, Iida H: Characterization of measles viruses in establishment of persistent infections in human lymphoid cell line. J Gen Virol 1976, 33(3):361-379.
• [2]Wadey CN, Faragher JT: Australian infectious bronchitis viruses: plaque formation and assay methods. Res Vet Sci 1981, 30(1):66-69.
• [3]Beales LP, Wood DJ, Minor PD, Saldanha JA: A novel cytopathic microtitre plate assay for hepatitis A virus and anti-hepatitis A neutralizing antibodies. J Virol Methods 1996, 59(1–2):147-154.
• [4]Schalk JA, de Vries CG, Jongen PM: Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay. Biologicals 2005, 33(2):71-79.
• [5]Sood DK, Aggarwal RK, Kumar S, Sokhey J: A rapid test for measuring the infectivity of Yellow Fever vaccine. Vaccine 1995, 13(5):427-428.
• [6]Ranheim T, Mathis PK, Joelsson DB, et al.: Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq). J Virol Methods 2006, 131(2):193-201.
• [7]Da CX, Kramer MF, Zhu J, Brockman MA, Knipe DM: Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000, 74(17):7963-7971.
• [8]Delagrave S, Hernandez H, Zhou C, et al.: Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model. PLoS One 2012, 7(10):e46714.
• [9]Mundle ST, Hernandez H, Hamberger J, et al.: High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoS One 2013, 8(2):e57224.
• [10]Smiley JR: Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase? J Virol 2004, 78(3):1063-1068.
• [11]Manservigi R, Argnani R, Marconi P: HSV recombinant vectors for gene therapy. Open Virol J 2010, 4:123-156.
• [12]Validation of Analytical Procedures, the International Conference on Harmonisation. 2005.
• [13]Chapter 5.3, Statistical analysis of results of biological assays and tests, European Pharmacopoeia. 8th edition. 2013.
• [14]Da Costa X, Jones CA, Knipe DM: Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 1999, 96(12):6994-6998.
• [15]Haynes JR, Arrington J, Dong L, Braun RP, Payne LG: Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 2006, 24(23):5016-5026.
• [16]Hoshino Y, Dalai SK, Wang K, et al.: Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005, 79(1):410-418.